References
1. Shteinberg M, Haq IJ, Polineni D, Davies JC. Cystic fibrosis. Lancet. 2021;397(10290):2195-211.2. NCFS. Nederlandse CF Registratie Jaarrapport 2022. Baarn, Nederland; 2023.3. EMA. Summary of Product Characteristics - SYMKEVI.: European Medicines Agency; 2018. Contract No.: EMEA/H/C/004682 - X/0015/G.4. FDA. CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW SYMDEKO (TEZACAFTOR/IVACAFTOR). 2017 28-06-2017.5. Walker S, Flume P, McNamara J, Solomon M, Chilvers M, Chmiel J, et al. A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11years with cystic fibrosis. J Cyst Fibros. 2019;18(5):708-13.6. Chan Kwong AHP, Calvier EAM, Fabre D, Gattacceca F, Khier S. Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine. J Pharmacokinet Pharmacodyn. 2020;47(5):431-46.7. Vonk SEM, van der Meer-Vos M, Bos LDJ, Neerincx AH, Majoor CJ, Maitland-van der Zee AH, et al. A Quantitative Method for the Analysis of Ivacaftor, Hydroxymethyl Ivacaftor, Ivacaftor Carboxylate, Lumacaftor, and Tezacaftor in Plasma and Sputum Using LC-MS/MS and Its Clinical Applicability. Ther Drug Monit. 2020.8. Vonk SEM, van der Meer-Vos M, Kos R, Neerincx AH, Terheggen-Lagro SWJ, Altenburg J, et al. Dried Blood Spot Method Development and Clinical Validation for the Analysis of Elexacaftor, Elexacaftor-M23, Tezacaftor, Tezacaftor-M1, Ivacaftor, Ivacaftor Carboxylate, and Hydroxymethyl Ivacaftor Using LC-MS/MS. Ther Drug Monit. 2024.9. FDA. CLINICAL PHARMACOLOGY REVIEW KALYDECO (IVACAFTOR). 2012 27-01-2012.10. Fohner AE, McDonagh EM, Clancy JP, Whirl Carrillo M, Altman RB, Klein TE. PharmGKB summary: ivacaftor pathway, pharmacokinetics/pharmacodynamics. Pharmacogenet Genomics. 2017;27(1):39-42.11. Rowland M. TTN. Clinical pharmacokinetics and pharmacodynamics. 4th Edition ed: Lippincott Williams & Wilkins, a Wolters Kluwer business; 2011.12. Vonk SEM, Altenburg J, Mathot RAA, Kemper EM, Amsterdam Mucociliary Clearance Disease Research G. Correlation between trough concentration and AUC for elexacaftor, tezacaftor and ivacaftor. J Cyst Fibros. 2024.13. Desimone ME, Sherwood J, Soltman SC, Moran A. Telemedicine in cystic fibrosis. J Clin Transl Endocrinol. 2021;26:100270.